Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Dutch Cancer Society · Leiden University Medical Center · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
150
total citations
- FWCI
- 37.60
- Percentile
- 100%
- References
- 22
Citations per year
Authors
20- EFEgbert F. SmitCorresponding
Dutch Cancer Society, Leiden University Medical Center, The Netherlands Cancer Institute, Oncode Institute
- EFEnriqueta Felip
Vall d'Hebron Institute of Oncology
- DUDipesh Uprety
The Barbara Ann Karmanos Cancer Institute
- MNMisako Nagasaka
University of California, Irvine
- KNKazuhiko Nakagawa
Kindai University Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Trastuzumab
- Cohort
- Internal medicine
- Clinical endpoint
- Oncology
- Lung cancer
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizerAward: P30 CA008748
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- CCelgene
- MSMemorial Sloan-Kettering Cancer CenterAward: CA008748
- RPRegeneron Pharmaceuticals
- TPTaiho Pharmaceutical
- JPJazz Pharmaceuticals
- LLLes Laboratories Pierre Fabre
- MTMersana Therapeutics
- MTMirati Therapeutics
- BBeiGene
- SPSyndax Pharmaceuticals
- RMRevolution Medicines
- PBPuma Biotechnology
- STSilverback Therapeutics
- SSeagen
- DDaiichi-Sankyo
- EEisaiAward: P30 CA008748
- SServier
- PPharmaMar
- OPOno Pharmaceutical
- NINational Institutes of HealthAward: P30 CA008748
- GGenentechAward: P30 CA008748
- SSamsung
- ESEMD Serono
- CPChugai Pharmaceutical
- TOTakeda Oncology
- ELEli Lilly Japan
- DSDaiichi Sankyo Company
- DSDaiichi Sankyo Europe